Equity, Efficacy Concerns a Potential Challenge for New Vaccine Rollout

A NEW VACCINE SHIPPED out this week looks to be a valuable tool as the U.S. aims for herd immunity against COVID-19, but providers may be challenged by questions of equity and a perception that the shot is less effective than its counterparts. Johnson & Johnson's COVID-19 vaccine received federal emergency-use approval late last week, joining candidates from Moderna and Pfizer to become the third coronavirus vaccine publicly available in the U.S.
Read more...

;